UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Phase II Study of Neoadjuvant Letrozole for Post-Menopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ

Participants in this research have ductal carcinoma in situ (DCIS), an early change in the breast that could become breast cancer in the future. DCIS cells are sensitive to hormones, and therefore may be treatable with anti-hormonal medications. Standard treatment for DCIS includes surgery to remove the DCIS cells from the breast, or surgery followed by radiation therapy. The purpose of this study is to test whether neoadjuvant (neoadjuvant means given before surgery) treatment with the aromatase inhibitor (anti-hormonal medication) letrozole has an effect, either good or bad, on the participants and on the DCIS.

Mammograms are the standard method of detecting and measuring DCIS. The researchers conducting this study would also like to learn more about whether Magnetic Resonance Imaging (MRI) may be better for evaluating and measuring DCIS, compared to mammograms. (An MRI scan is a radiology technique that produces images of the body using magnets, not X-rays.)

Approximately six people will take part in this study conducted by investigators at the University of Iowa. Approximately 106 women will take part in this study nationwide.

Start Date
May 15, 2013
End Date
February 1, 2015
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Alexandra Thomas, MD
Contact Info

Clarine Halvorsen, 319-356-3944

breast ; cancer ; ductal carcinoma in situ (DCIS) ; IRB#201209811 ; letrozole ; thomas ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.